Citations

Showing 10 of 108162 citations.

An Analysis of Procedural Medicare Reimbursement Rates in Hand Surgery: 2000 to 2019
Thornburg, Danielle A. , Gupta, Nikita , Chow, Nathan , Haglin, Jack M. , Noland, Shelley S. , Haglin, Jack, Noland, Shelley, Chow, Nathan A

Mayo Clinic

HAND | February 26, 2021 | Volume: 17 | Issue: 6 | Pages: 1207-1213

10.1177/1558944721990807 | PMID 33631979 Get It

Background: Medicare reimbursement trends across multiple surgical subspecialties have been analyzed; however, little has been reported regarding the long-term trends in reimbursement of hand surgery procedures. The aim of this study is to analyze trends in Medicare reimbursement for commonly performed hand surgeries. Methods: Using the Centers for Medicare and Medicaid Services Physician and Other Supplier Public Use File, we determined the 20 hand surgery procedure codes most commonly billed to Medicare in 2016. Reimbursement rates were collected and analyzed for each code from The Physician Fee Schedule Look-Up Tool for years 2000 to 2019. We compared the change in reimbursement rate for each procedure to the rate of inflation in US dollars, using the Consumer Price Index (CPI) over the same time period. Results: The reimbursement rate for each procedure increased on average by 13.9% during the study period while the United States CPI increased significantly more by 46.7% ( P < .0001). When all reimbursement data were adjusted for inflation to 2019 dollars, the average reimbursement for all included procedures in this study decreased by 22.6% from 2000 to 2019. The average adjusted reimbursement rate for all procedures decreased by 21.92% from 2000 to 2009 and decreased by 0.86% on average from 2009 to 2019 ( P < .0001). Conclusion: When adjusted for inflation, Medicare reimbursement for hand surgery has steadily decreased over the past 20 years. It will be important to consider the implications of these trends when evaluating healthcare policies and the impact this has on access to hand surgery.
Bilateral transcranial magnetic stimulation of the supplementary motor area in children with Tourette syndrome
Kahl, Cynthia , Kirton, Adam , Pringsheim, Tamara , Zewdie, Ephrem , Swansburg, Rose , Wrightson, James G. , Langevin, Lisa Marie , MacMaster, Frank P. , Wrightson, James , Macmaster, Frank P , Croarkin, Paul E.

Mayo Clinic

Developmental Medicine & Child Neurology | February 26, 2021 | Volume: 63 | Issue: 7 | Pages: 808-815

10.1111/dmcn.14828 | PMID 33634500 Get It

Aim To explore the feasibility and possible effects of low‐frequency repetitive transcranial magnetic stimulation (rTMS) delivered to the supplementary motor area (SMA) on tic severity and motor system neurophysiology in children with Tourette syndrome. Method Ten children with Tourette syndrome (eight males, two females; 9–15y) participated in this open‐label, phase 1 clinical trial. Treatment consisted of 1800 low‐frequency (1Hz) neuronavigated robotic rTMS (100% resting motor threshold) to the SMA, bilaterally for 15 sessions. The primary outcome was a change in Yale Global Tic Severity Scale (YGTSS) total score from baseline to posttreatment. Secondary outcome measures included changes in magnetic resonance spectroscopy metabolite concentrations, TMS neurophysiology measures, TMS motor maps, and clinical assessments (anxiety, depression) from baseline to the end of treatment. Results The YGTSS score decreased from baseline after treatment ( p <0.001; Cohen's d =2.9). All procedures were well‐tolerated. Interpretation Robot‐driven, neuronavigated bilateral rTMS of the SMA is feasible in children with Tourette syndrome and appears to reduce tic severity. What this paper adds Repetitive transcranial magnetic stimulation (rTMS) is feasible to use in children with Tourette syndrome. rTMS is tolerated by children with Tourette syndrome. Precise targeting of the supplementary motor area using functional magnetic resonance imaging is also feasible in these children.
Multi-Omics Data Analysis of Gene Expressions and Alterations, Cancer-Associated Fibroblast and Immune Infiltrations, Reveals the Onco-Immune Prognostic Relevance of STAT3/CDK2/4/6 in Human Malignancies
Lawal, Bashir , Lin, Li-Ching, Lee, Jih-Chin, Chen, Jia‐Hong , Bekaii‐Saab, Tanios , Wu, Alexander T.H. , Ho, Ching-Liang, Bekaii-Saab, Tanios S , Wu, Alexander T H , Lee, Jih‐Chin , Chen, Jia-Hong , Ho, Ching‐Liang

Mayo Clinic

Cancers | February 25, 2021 | Volume: 13 | Issue: 5 | Pages: 954

10.3390/cancers13050954 | PMID 33668805 Get It

Signal transducer and activator of transcription 3 (STAT3)/Cyclin-dependent kinases are multifunctional proteins that play an important implicative role in cancer initiations, progression, drug resistance, and metastasis, and has been extensively explored in cancer therapy. However, the genetic alterations of STAT3/CDK2/4/6 and its role in predicting immune infiltration and immunotherapeutic response are yet to be well exploited. In this study, we use in silico methods to analyze differential expression, prognostic value, genetic and epigenetic alterations, association with tumor-infiltrating immune cells, and cancer-associated fibroblast (CAF) infiltrations of STAT3/CDK2/4/6 in multiple cancer types. Our results revealed that the expression of STAT3/CDK2/4/6 was altered in various cancers and is associated with poor overall and disease-free survival of the cohorts. Moreover, genetic alterations in STAT3/CDK2/4/6 co-occurred with a number of other genetic alterations and are associated with poorer prognoses of the cohorts. The protein-protein interaction (PPI) network analysis suggests CDK2/4/6/STAT3 may directly interact with factors that promote tumorigenesis and immune response. We found that STAT3/CDK2/4/6 expressions were associated with infiltrations of CAF and the various immune cells in multiple cancers and it’s associated with poor response to immunotherapy. Collectively, our study suggested that STAT3/CDK2/4/6 are important onco-immune signatures that play central roles in tumor immune invasion, poor prognoses and, immune therapy response. Findings from the present study may therefore be clinically useful in prognosis assessment and follow-up management of immunotherapy.
The Medial Femoral Condyle Free Flap for Reconstruction of Recalcitrant Defects in the Head and Neck
Singh, Kuldeep , Huang, Tony Chieh‐Ting , Meaike, Jesse D. , Mills, Andrew , Nathan, John , Lettieri, Salvatore C. , Arce, Kevin , Moran, Steven L. , Nathan, John M, Nathan, John M.

Mayo Clinic

Annals of Plastic Surgery | February 25, 2021 | Volume: 87 | Issue: 3 | Pages: 291-297

10.1097/sap.0000000000002736 | PMID 34397517 Get It

Background Small recalcitrant defects of the mandible and maxilla may be secondary to tumor, trauma, infection, and congenital origin. Vascularized bone grafting has been shown to effectively manage these defects; however, donor sites are limited. The vascularized medial femoral condyle (MFC) provides adequate cortical cancellous bone with the option of a skin island, consistent anatomy, and minimal donor site morbidity. This article outlines the use of the MFC flap for maxillomandibular reconstruction. Methods A retrospective chart review of patients who required segmental maxillomandibular reconstruction with the MFC flap was conducted. A total of 9 patients (5 men and 5 women) with an average age of 45.3 years were identified. The etiology of the defects, flap sizes, and postoperative outcomes were recorded. Results Three patients had osteoradionecrosis of the neomandible after irradiation of the free fibula reconstruction, 3 patients had defects after cancer extirpation (1 mandible, 2 maxillary), 1 patient had a maxillary defect from trauma, and 2 patients had a residual cleft palate defect. All defects failed initial treatment with nonvascularized bone grafts. The average dimensions of the MFC flaps were 1.2 × 2.5 × 4 cm. Two of 9 flaps included a skin island. Eight flaps survived completely, but 1 patient suffered from flap failure requiring debridement and resulted in an oroantral fistula. Four patients received endosseous dental implants. Average time to union was 6.7 months, and average time to implant was 6.75 months. The average follow-up time was 24.9 months. Conclusions The MFC flap is useful in the reconstruction of small segmental maxillomandibular defects and for the salvage of a neomandible after osteoradionecrosis. The MFC flap provides a reliable platform for endosseous dental implants and serves as an alternative source of vascularized bone reconstruction in the head and neck.
Negative-Pressure Wound Therapy in the Prevention and Management of Complications From Prosthetic Breast Reconstruction
Chicco, Maria , Huang, Tony Chieh‐Ting , Cheng, Hsu-Tang

Mayo Clinic

Annals of Plastic Surgery | February 25, 2021 | Volume: 87 | Issue: 4 | Pages: 478-483

10.1097/sap.0000000000002722 | PMID 34060773 Get It

Background Complications from prosthetic breast reconstruction are distressing for patients, and their management is challenging. For decades, negative-pressure wound therapy (NPWT) has been successfully used for the closure of complex wounds. This study analyzes the outcomes of NPWT use in the prevention and management of complications from prosthetic breast reconstruction. Method A systematic search of studies published until August 2020 was conducted using the PubMed/MEDLINE, EMBASE, and Ebscohost/CINAHL databases and using the following key words: “negative-pressure wound therapy,” “breast reconstruction,” and “prosthesis” (including breast implants and tissue expanders). Analyzed endpoints were outcomes of NPWT use in prosthetic breast reconstruction compared with conventional dressings. The methodological quality of included studies was assessed independently. Comparative studies were further meta-analyzed to obtain pooled odds ratios (ORs) describing the effectiveness of NPWT in prosthetic breast reconstruction. Results/Discussion Ten studies were included with a total of 787 patients (1230 breasts) undergoing prosthetic breast reconstruction with breast implants or tissue expanders. Three case-control studies focused on preventing breast wound complications. The meta-analysis of the 3 studies included 502 breasts receiving NPWT and 698 breasts receiving conventional wound care. The meta-analysis favored NPWT for less mastectomy flap necrosis (5.6% vs 14.3%; OR, 0.46; 95% confidence interval, 0.27 –0.77; P = 0.004; I 2 = 0%) and less overall wound complications (10.6% vs 21.1%; OR, 0.49; 95% confidence interval, 0.35–0.70; P < 0.00001; I 2 = 0%). In the management of nipple-areolar complex venous congestion, 1 case report demonstrated 85% rescue of nipple-areolar complex after using NPWT (−75 mm Hg) for a total of 12 days. In the management of periprosthetic infections, 2 case series used NPWT with instillation. It accelerated the treatment of infection and maintained the breast cavity for future reconstruction. Conventional NPWT also showed good salvage outcome in four studies. Conclusions Current evidence suggests that prophylactic use of NPWT in prosthetic breast reconstruction reduces the rate of overall wound complications and mastectomy flap necrosis. In the management of complications from prosthetic breast reconstructions, NPWT may be a promising option showing beneficial results. Additional high-quality trials are warranted to corroborate the findings of this systematic review.
Mismatch Repair (MMR) Gene Alteration and BRAF V600E Mutation Are Potential Predictive Biomarkers of Immune Checkpoint Inhibitors in MMR-Deficient Colorectal Cancer
Şahin, İbrahim Halil , Goyal, Subir , Pumpalova, Yoanna S , Das, Satya , Haraldsdóttir, Sigurdís , Ahn, Daniel H. , Ciombor, Kristen K. , Chen, Zhengjia , Draper, Amber , Bekaii‐Saab, Tanios , El‐Rayes, Bassel F. , El-Rayes, Bassel F , Bekaii-Saab, Tanios S , Sonbol, Mohamad Bassam , Berlin, Jordan D. , Lesinski, Gregory B , Wu, Christina , Sahin, Ibrahim Halil

Mayo Clinic

The Oncologist | February 25, 2021 | Volume: 26 | Issue: 8 | Pages: 668-675

10.1002/onco.13741 | PMID 33631043 Get It

Abstract Background Immune checkpoint inhibitor (ICI) therapy is highly effective in metastatic mismatch repair-deficient (MMR-D) colorectal cancer (CRC). In this study, we evaluated molecular and clinical predictors of ICI response in MMR-D CRC. Materials and Methods Patient databases at four cancer institutions were queried. The Fisher exact test was performed to test the association of clinical and molecular markers. The Kaplan-Meier method was used to estimate progression-free survival (PFS) and compared by the log-rank test. Twelve- and 24-month PFS rates were compared by the Z test. Results A total of 60 patients with CRC with MMR-D/microsatellite instability-high who previously received ICIs were identified. Patients with liver metastasis had a lower overall response rate as compared with other sites of metastasis (36.4% vs. 68.7%; p = .081). Patients with MLH1/PMS2 loss had worse 1-year and 2-year PFS rates compared with patients with MSH2/MSH6 loss (84.2% vs. 57.8% and 78.2% vs. 54.2%, respectively; p &lt; .001). There were improved 1-year and 2-year PFS rates in patients with wild-type BRAF when compared with patients with BRAF V600E mutation (73.3% vs. 40%, and 73.3% vs. 26.7%; respectively; p &lt; .001). Patients aged &gt;65 had significantly worse PFS rates as compared with patients aged ≤65 (p &lt; .001). Conclusion BRAF V600E mutation, MLH1 and/or PMS2 loss, as well as age &gt;65 years and liver metastasis, may be predictive of duration of ICI response in patients with MMR-D CRC. Larger cohorts are needed to confirm our findings. Implications for Practice The results of this study reveal clinically important biomarkers that potentially predict immune checkpoint inhibitor response in patients with mismatch repair-deficient colorectal cancer.
Occult lymph node metastasis in radiologic stage I non‐small cell lung cancer: The role of endobronchial ultrasound
KUKHON, FAEQ R , Lan, Xinyue, Arunthari, Vichaya, Fernández-Bussy, Sebastián , Patel, Neal M. , Helgeson, Scott A.

Mayo Clinic

The Clinical Respiratory Journal | February 25, 2021 | Volume: 15 | Issue: 6 | Pages: 676-682

10.1111/crj.13344 | PMID 33630405 Get It

AbstractRationaleThe use of endobronchial ultrasound‐guided transbronchial needle aspiration (EBUS‐TBNA) is currently recommended for staging non‐small cell lung cancer (NSCLC) in centrally located tumors, tumors >3 cm, or with radiologic evidence of lymph node (LN) metastasis. Current guidelines do not recommend staging EBUS‐TBNA in patients with stage I NSCLC who do not have any of the aforementioned conditions.ObjectiveWe hypothesize that using EBUS‐TBNA is useful for detecting occult metastasis in radiologic stage I NSCLC.MethodsIn this single‐center, retrospective study, charts of patients ≥18 years old who underwent staging EBUS‐TBNA from January 2005 to May 2019 were reviewed. Only patients with combined positron‐emission tomography and computed tomography (PET/CT) scans consistent with radiologic stage I NSCLC were included. Identified variables included: age, gender, personal history of any cancer, smoking history, tumor location, tumor centrality, tumor size, tumor PET activity, histopathologic type of NSCLC, and LN biopsy results. Patients whose LN samples showed a diagnosis other than NSCLC were excluded. The association between LN positivity, and each of the variables was assessed using Pearson's correlation for categorical variables, and logistic regression analysis for continuous variables.ResultsFrom the 2,892 initially screened patients, 188 were included. Of those, 13 (6.9%; 95% CI, 4%–11%) had a malignancy‐positive LN biopsy. The number needed to test (NNT) in order to detect one case of any occult metastasis was 15. Among the included variables, a significant association was found between LN positivity and tumor centrality, with central tumors found in 61.5% of patients with positive LN (n = 8) (p < 0.01). This association stayed significant after adjusting for age, gender, smoking history, tumor size, tumor location, and PET activity (p = 0.015). Among patients with malignancy‐positive LN biopsies, five (38.5%; 95% CI, 17.6%–64.6%) were upstaged to N1, and eight (61.5%; 95% CI, 35.4%–82.4%) were upstaged to N2, with NNT of 23 to detect one case of occult N2 metastasis. Subgroup analysis comparing LN‐positive patients based on their N stage did not show statistically significant association with any of the variables.ConclusionBased on our results and along with the existing evidence, EBUS‐TBNA should be recommended as part of the routine staging in all patients with radiologic stage I NSCLC.
Markers of Bile Acid Metabolism in Pediatric Diarrhea Predominant Irritable Bowel Syndrome and Healthy Controls
Beinvogl, Beate C. , Manini, Mhd Louai , Camilleri, Michael , Harmsen, William S. , Absah, Imad , Burch, Elizabeth, Schechter, Neil L. , Nurko, Samuel , Donato, Leslie J. , Harmsen, William Scott, Nurko, Samuel

Mayo Clinic

Journal of Pediatric Gastroenterology and Nutrition | February 25, 2021 | Volume: 72 | Issue: 6 | Pages: 859-865

10.1097/mpg.0000000000003067 | PMID 33976086 Get It

ABSTRACTObjectives:Excessive fecal bile acids in adults have been associated with diarrhea‐predominant irritable bowel syndrome (IBS‐D), but their role in pediatric IBS‐D is unknown. Serum markers including 7α‐hydroxy‐4‐cholesten‐3‐one (C4) and fibroblast growth factor‐19 (FGF‐19) were validated in adults to detect bile acid diarrhea (BAD) compared to 48‐hour fecal bile acid collection (48FBA). Our aims were to assess fasting serum C4 and FGF–19 and 48FBA in a pediatric population, to compare measurements in IBS‐D patients and healthy controls (HC), and to determine the prevalence of BAD among children with IBS‐D.Methods:Using a cross‐sectional design, 26 patients with IBS‐D and 56 HC were recruited in two pediatric tertiary care centers. Fasting serum C4 and FGF‐19 and 48FBA were obtained. Participants completed a 7‐day bowel diary coinciding with stool collection. Associations were analyzed using Spearman correlations.Results:Mean age was 14.7 ± 2.5 years (42.3% female) in IBS‐D and 12.6 ± 2.4 years (39.3% female) in HC. There was a significant correlation of C4 with 48FBA (r = 0.48, P < 0.05) and an inverse association with FGF‐19 (r = –0.43, P < 0.05). No significant differences were noted in C4 (P = 0.32), FGF‐19 (P = 0.1), or 48FBA (P = 0.5) between IBS‐D and HC groups; however, 20% of IBS‐D patients had elevated C4 and 28% had low FGF‐19 values.Fecal primary BA was significantly correlated with stool frequency (r = 0.45, P < 0.002).Conclusions:Correlations of C4 with 48FBA and FGF‐19 are confirmed in a pediatric population. Twenty percent of pediatric patients with IBS‐D had abnormal fasting serum C4. This serum test could be applied to identify BAD in pediatric IBS‐D.
Genetic architectures of proximal and distal colorectal cancer are partly distinct
Huyghe, Jeroen R. , Harrison, Tabitha A. , Figueiredo, Jane C. , Schmit, Stephanie L. , Chen, Sai , Barfield, Richard , Cross, Amanda J. , Diergaarde, Brenda , Duggan, David , Harlid, Sophia , Imaz, Liher , Kang, Hyun Min , Levine, David , Perduca, Vittorio , Perez‐Cornago, Aurora , Slattery, Martha L. , Duijnhoven, Fränzel J.B. van , Guelpen, Bethany Van , Anderson, Kristin E. , Arnau‐Collell, Coral, Banbury, Barbara L. , Berndt, Sonja I. , Bishop, D. Timothy , Boehm, Juergen , Boeing, Heiner , Brenner, Hermann , Buch, Stephan , Burnett‐Hartman, Andrea N. , Carr, Prudence R. , Castells, Antoni , Chang‐Claude, Jenny , Curtis, Keith R. , Chapelle, Albert de la , Easton, Douglas F. , English, Dallas R. , Gala, Manish , Gallinger, Steven , Gauderman, W. James, Goodman, Phyllis J. , Grove, John, Gsur, Andrea , Gunter, Marc J. , Haile, Robert W. , Hampe, Jochen , Hoffmeister, Michael , Hsu, Wan‐Ling, Huang, Wen‐Yi , Joshi, Amit D. , Kühn, Tilman , Küry, Sébastien , Lejbkowicz, Flavio, Li, Li , Lindblom, Annika , Lindor, Noralane M. , Markowitz, Sanford D. , Moreno, Lorena , Murphy, Neil , Nassir, Rami , Offit, Kenneth, Parfrey, Patrick S. , Pearlman, Rachel , Phipps, Amanda I. , Prentice, Ross L. , Qi, Lihong , Rennert, Gad , Rennert, Hedy S., Ríboli, Elio , Schafmayer, Clemens, Seminara, Daniela, Song, Mingyang , Su, Yu‐Ru, Thibodeau, Stephen N. , Thomas, Duncan C. , Trichopoulou, Antonia , Visvanathan, Kala, Vodička, Pavel , Vodičková, Ludmila, Weigl, Korbinian , Weinstein, Stephanie J. , Woods, Michael O. , Wu, Anna H. , Nickerson, Deborah A. , Scacheri, Peter C. , Kundaje, Anshul , Casey, Graham , Gruber, Stephen B. , Hayes, Richard B. , Peters, Ulrike , Visvanathan, Kala , Brenner, Hermann , Buchanan, Daniel D , Chan, Andrew T , Gsur, Andrea , Hampe, Jochen , Hoffmeister, Michael , Huang, Wen-Yi , Jenab, Mazda , Murphy, Neil , Peters, Ulrike , Rennert, Gad , English, Dallas R , Gunter, Marc J , Haile, Robert W , Harrison, Tabitha A , Van Guelpen, Bethany , Visvanathan, Kala , Kury, Sebastien , Bishop, D Timothy , Song, Mingyang , Hayes, Richard B , Perez-Cornago, Aurora , Nassir, Rami , Kundaje, Anshul , Riboli, Elio , Vodicka, Pavel , Diergaarde, Brenda , Lindblom, Annika , Bien, Stephanie A. , Hampel, Heather , Conti, David V. , Qu, Conghui , Lin, Yi , Baron, John A. , Sakoda, Lori C. , Schumacher, Fredrick R. , Toland, Amanda Ewart , Agudo, Antonio , Albanes, Demetrius , Alonso, M. Henar , Arndt, Volker , Bassik, Michael Cory , Bezieau, Stéphane , Boutron‐Ruault, Marie‐Christine , Brezina, Stefanie , Buchanan, Daniel D. , Caan, Bette J. , Campbell, Peter T. , Castellvı́-Bel, Sergi , Chan, Andrew T. , Chanock, Stephen Jacob , Feskens, Edith J. M. , Giles, Graham G. , Grady, William M. , Hopper, John L. , Hudson, Thomas J , Jenab, Mazda , Jenkins, Mark A. , Keku, Temitope O , Kooperberg, Charles , Marchand, Loı̈c Le , Li, Christopher I , Lieb, Wolfgang , Männistö, Satu , Milne, Roger L. , Ogino, Shuji , Panico, Salvatore , Pharoah, Paul D.P. , Platz, Elizabeth A. , Potter, John D. , Raskin, Leon , Schoen, Robert E. , Tangen, Catherine M. , Ulrich, Cornelia M. , Vymetalkova, Veronika Polakova , White, Emily E. , Wolk, Alicja , Abecasis, Gonçalo R. , Hsu, Li , Moreno, Vı́ctor , Newcomb, Polly A.

Mayo Clinic

Gut | February 25, 2021 | Volume: 70 | Issue: 7 | Pages: 1325-1334

10.1136/gutjnl-2020-321534 | PMID 33632709 Get It

Objective An understanding of the etiologic heterogeneity of colorectal cancer (CRC) is critical for improving precision prevention, including individualized screening recommendations and the discovery of novel drug targets and repurposable drug candidates for chemoprevention. Known differences in molecular characteristics and environmental risk factors among tumors arising in different locations of the colorectum suggest partly distinct mechanisms of carcinogenesis. The extent to which the contribution of inherited genetic risk factors for CRC differs by anatomical subsite of the primary tumor has not been examined. Design To identify new anatomical subsite-specific risk loci, we performed genome-wide association study (GWAS) meta-analyses including data of 48 214 CRC cases and 64 159 controls of European ancestry. We characterised effect heterogeneity at CRC risk loci using multinomial modelling. Results We identified 13 loci that reached genome-wide significance (p<5×10 −8 ) and that were not reported by previous GWASs for overall CRC risk. Multiple lines of evidence support candidate genes at several of these loci. We detected substantial heterogeneity between anatomical subsites. Just over half (61) of 109 known and new risk variants showed no evidence for heterogeneity. In contrast, 22 variants showed association with distal CRC (including rectal cancer), but no evidence for association or an attenuated association with proximal CRC. For two loci, there was strong evidence for effects confined to proximal colon cancer. Conclusion Genetic architectures of proximal and distal CRC are partly distinct. Studies of risk factors and mechanisms of carcinogenesis, and precision prevention strategies should take into consideration the anatomical subsite of the tumour.